Business
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026Improved balance sheet through multiple direct offerings; completed payments of outstanding debtHOUSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using
About this update from Fibrobiologics, Inc.
[{"type":"image","alt":"FibroBiologics, Inc.","displaySize":"","headline":null,"caption":"FibroBiologics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":77,"url":"https://media.zenfs.com/en/globenewswire.com/ea452943381e269d15ec4a2f87674425"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xw_QEbMhw7ViThavcOHCOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ea452943381e269d15ec4a2f87674425","width":300,"height":77}},"lazy":false},{"type":"text","content":"Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026","length":135,"tagName":"p"},{"type":"text","content":"Improved balance sheet through multiple direct offerings; completed payments of outstanding debt","length":96,"tagName":"p"},{"type":"text","content":"HOUSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced full year 2025 financial results and provided a corporate update.","length":397,"tagName":"p"},{"type":"text","content":"Recent Highlights ","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Secured both public and private Human Research Ethics Committee (HREC) approvals in Australia for a Phase 1/2 clinical trial evaluating CYWC628 for the treatment of refractory diabetic foot ulcers (DFU), enabling the enrollment of 120 patients at up to 10 sites across Australia.","length":279,"tagName":"p"}]},{"val":[{"type":"text","content":"Filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to advance the clinical development of CYPS317 in patients with psoriasis.","length":175,"tagName":"p"}]},{"val":[{"type":"text","content":"Raised a total of $7.2M through multiple direct offerings.","length":58,"tagName":"p"}]},{"val":[{"type":"text","content":"Repaid all outstanding debt.","length":28,"tagName":"p"}]},{"val":[{"type":"text","content":"Expanded the patent portfolio with the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) covering a pr...